CPHA Canvax
CPHA Canvax
PDF

"Among 306 Pfizer-BioNTech clinical trial participants, adverse reactions after dose 3 were similar to those after dose 2. During August 12–September 19, 2021, among 12,591 v-safe registrants who completed a health check-in survey after all 3 doses of an mRNA COVID-19 vaccine, 79.4% and 74.1% reported local or systemic reactions, respectively, after the third dose; 77.6% and 76.5% reported local or systemic reactions after the second dose, respectively. Voluntary reports to v-safe found no unexpected patterns of adverse reactions after an additional dose of COVID-19 vaccine. CDC will continue to monitor vaccine safety, including for additional COVID-19 doses." - United States Centres for Disease Control and Prevention


Download

Related Resources

Bookmark

Evidence

PDF

Category

Vaccine Safety and Development,Vaccine Safety,Vaccine Safety,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Vaccine Monitoring and Surveillance,Vaccine Monitoring,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Vaccine Safety
Vaccine Safety
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Vaccine Monitoring and Surveillance
Vaccine Monitoring
Outbreaks and Pandemics
COVID-19

0 Comments

Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.